Baron ... I submitted 3 questions earlier in the week but they were not addressed. The session was entirely about technical progress and business development was not on the agenda for the quarterly review. My questions (which were not addressed) were:
Q1 ... At the last quarterly you described the feedback from some pharma companies as "super,super encouraging". Have the follow up discussions been just as encouraging and what feedback are we getting?
Q2 ... Is a financial deal (licence, programme partner, company JV etc) likely in the next 6 months, noting that raising more money at 5.5c to run 2 then 3 clinical programmes will be terribly diluting?
Q3 ... On the ASX it seems that there is active price suppression occurring. Are there any tactics to counteract this behaviour? Each good news announcement has about 1 day of sunshine then the price drops to below where it was prior to the announcement. Price drops also occur when turnover volume increases - how does that happen?
I'll have to wait till the next quarterly for answers.
PYC Price at posting:
6.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)